Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials
J Eur Acad Dermatol Venereol
.
2021 Feb;35(2):e130-e133.
doi: 10.1111/jdv.16865.
Epub 2020 Sep 7.
Authors
L A Beck
1
,
J I Silverberg
2
3
4
5
,
E L Simpson
6
,
G Yosipovitch
7
,
L Eckert
8
,
I Guillemin
9
,
Z Chen
10
,
M Ardeleanu
10
,
S Plaum
11
,
N Graham
10
,
M Ruddy
10
,
G Pirozzi
11
,
A Gadkari
10
Affiliations
1
Department of Dermatology, University of Rochester Medical Center, Rochester, NY, USA.
2
Department of Dermatology, The George Washington School of Medicine and Health Sciences, Washington, DC, USA.
3
Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
4
Department of Medical Social Sciences, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
5
Northwestern Medicine Multidisciplinary Eczema Center, Chicago, IL, USA.
6
Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.
7
Miami Itch Center, Dr Phillip Frost Department of Dermatology & Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
8
Sanofi, Chilly-Mazarin, France.
9
Sanofi, Lyon, France.
10
Regeneron Pharmaceuticals, Tarrytown, NY, USA.
11
Sanofi, Bridgewater, NJ, USA.
PMID:
32789996
PMCID:
PMC7891630
DOI:
10.1111/jdv.16865
No abstract available
Publication types
Letter
MeSH terms
Adult
Antibodies, Monoclonal, Humanized
Dermatitis, Atopic* / drug therapy
Humans
Randomized Controlled Trials as Topic
Sleep
Substances
Antibodies, Monoclonal, Humanized
dupilumab
Grants and funding
Sanofi
Regeneron Pharmaceuticals